Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation.
The use of immunosuppressive agents in renal transplant recipients increases the risk of tumor development. The global incidence of tumors in renal transplant recipients is 4% to 18% and is especially high for skin lesions, non-Hodgkin lymphoma, and genital malignancy but not for lung, breast, prostate gland, or colorectal lesions. Between May 1983 and May 2008, we performed 663 renal transplantation procedures; 85.5% were first transplantation procedures. Mean patient age was 46.93 years. Patients received treatment with combinations of immunosuppressive agents including corticosteroids, cyclosporine, OKT3, mycophenolate mofetil, tacrolimus, azathioprine, and basiliximab or daclizumab. The incidence of nonskin tumors was 4.07%. Mean age at diagnosis was 61.41 years, mean interval between transplantation and diagnosis of tumor was 6.04 years, and mean duration of graft function was 7.59 years. Mortality was due to tumor in 20.14% of patients, and of those with cancer, 74.07% died; all patients who died had a functioning graft. The most common malignant lesions were lung cancer in men and breast cancer in women. The incidence of nonskin tumors was lower than that in published series, probably because of routine screening of patients while on the waiting list and in transplant recipients with functioning grafts.
Fraile
P
P
Service of Nephrology, University Hospital of Salamanca, Salamanca, Spain. pilarfg@usal.es
García-Cosmes
P
P
Martín
P
P
García-Bernalt
V
V
Tabernero
J M
JM
D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D016031:Liver Transplantation / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality; D012189:Retrospective Studies; D012727:Sex Characteristics; D012871:Skin Diseases / Q000139:chemically induced / Q000453:epidemiology; D013030:Spain; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D001379:Azathioprine; D016559:Tacrolimus